Diabetes drugs containing saxagliptin (Onglyza) and
alogliptin (Nesina) may increase the risk of heart failure, the US FDA announced
on 5th April, 2016.
A U.S. Food and Drug Administration
(FDA) safety review has found that type 2 diabetes medicines containing
saxagliptin and alogliptin may increase the risk of heart failure, particularly
in patients who already have heart or kidney disease.
Heart failure can result in the
heart not being able to pump enough blood to meet the body’s needs. As a
result, a new warning is being added to the drug labels about this safety
issue.
Saxagliptin and Alogliptin are part
of the class of dipeptidyl peptidase-4 (DPP-4) inhibitor drugs, which are used
with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Patients taking these medicines should contact their health care
professionals right away, if they develop signs and symptoms of heart failure
such as:
- Unusual shortness of breath during daily activities
- Trouble breathing when lying down
- Tiredness, weakness, or fatigue
- Weight gain with swelling in the ankles, feet, legs, or abdomen
Patients should not stop taking
their medicine without first talking to their health care professionals.
Health care professionals should consider discontinuing the medicine in patients who
develop heart failure and monitor their diabetes control. If a patient’s blood
sugar level is not well-controlled with their current treatment, other diabetes
medicines may be required.
The original article can be accessed
here.
...
Click here to Subscribe news feed from "Clinicianonnet; so that you do not miss out anything that can be valuable to you !!
...
Posts
